Emergent BioSolutions/$EBS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Emergent BioSolutions
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Ticker
$EBS
Sector
Primary listing
NYSE
Industry
Biotechnology
Headquarters
Employees
900
ISIN
US29089Q1058
Website
EBS Metrics
BasicAdvanced
$345M
-
-$2.46
2.09
-
Price and volume
Market cap
$345M
Beta
2.09
52-week high
$15.10
52-week low
$4.02
Average daily volume
1.4M
Financial strength
Current ratio
6.316
Quick ratio
3.153
Long term debt to equity
120.445
Total debt to equity
120.445
Interest coverage (TTM)
-0.69%
Profitability
EBITDA (TTM)
61.8
Gross margin (TTM)
36.67%
Net profit margin (TTM)
-13.63%
Operating margin (TTM)
-4.31%
Effective tax rate (TTM)
-111.24%
Revenue per employee (TTM)
$1,070,000
Management effectiveness
Return on assets (TTM)
-1.61%
Return on equity (TTM)
-21.63%
Valuation
Price to revenue (TTM)
0.352
Price to book
0.63
Price to tangible book (TTM)
5.13
Price to free cash flow (TTM)
2.202
Free cash flow yield (TTM)
45.41%
Free cash flow per share (TTM)
288.33%
Growth
Revenue change (TTM)
-18.56%
Earnings per share change (TTM)
-77.52%
3-year revenue growth (CAGR)
-18.10%
10-year revenue growth (CAGR)
7.70%
3-year earnings per share growth (CAGR)
-6.09%
10-year earnings per share growth (CAGR)
11.25%
What the Analysts think about EBS
Analyst ratings (Buy, Hold, Sell) for Emergent BioSolutions stock.
Bulls say / Bears say
Emergent BioSolutions' Narcan nasal spray received FDA approval for over-the-counter use, potentially expanding its market reach and boosting sales. (bloomberg.com)
The appointment of Joseph Papa, known for successful turnarounds at Bausch + Lomb and Bausch Health, as CEO is expected to drive strategic improvements and operational efficiency. (markets.businessinsider.com)
Emergent BioSolutions reported a significant 83% year-over-year increase in Q1 2024 revenue, indicating strong financial performance and potential for sustained growth. (markets.businessinsider.com)
The company announced layoffs of approximately 300 employees and the closure of several manufacturing facilities, which may indicate underlying operational challenges. (reuters.com)
Emergent BioSolutions' stock price experienced a 9% decline following the abrupt resignation of CEO Robert Kramer, raising concerns about leadership stability. (fool.com)
The company reported a net loss of $587 million over the trailing twelve months, reflecting significant financial challenges and potential risks for investors. (finance.yahoo.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
EBS Financial Performance
Revenues and expenses
EBS Earnings Performance
Company profitability
EBS News
AllArticlesVideos
![Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2Fs%2Fg%2Fr%2Fpress2-3149185.jpg&w=3840&q=75)
Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
GlobeNewsWire·1 week ago
Emergent BioSolutions Announces Addition to Russell 3000® Index
GlobeNewsWire·2 weeks ago
Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Emergent BioSolutions stock?
Emergent BioSolutions (EBS) has a market cap of $345M as of July 01, 2025.
What is the P/E ratio for Emergent BioSolutions stock?
The price to earnings (P/E) ratio for Emergent BioSolutions (EBS) stock is 0 as of July 01, 2025.
Does Emergent BioSolutions stock pay dividends?
No, Emergent BioSolutions (EBS) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next Emergent BioSolutions dividend payment date?
Emergent BioSolutions (EBS) stock does not pay dividends to its shareholders.
What is the beta indicator for Emergent BioSolutions?
Emergent BioSolutions (EBS) has a beta rating of 2.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.